Wumin

Dr. Wu is an associate professor at School of Life Science and Technology, China Pharmaceutical University, and a master's supervisor in microbiology and biochemical pharmacy. Dr. Wu specializes in anti-tumor antibody drugs, antibacterial drugs against drug-resistant bacteria and computer aided drug design.

1) Zhuobin Xu, Zegen Wang, Xuelian Jia, Luxuan Wang, Zhiguo Chen, Shijing Wang, Min Wang*, Juan Zhang*, Min Wu*. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth，Cancer Letters, 2016, (372) 118–127.

2）Shijing Wang, Rihong Zhou, Fumou Sun, Renjie Li, Min Wang*, Min Wu** .The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models, Cancer Letters, 2017, (409) 125-136.

3）Rihong Zhou, Shijing Wang, Hui Wen, Min Wang∗, Min Wu∗. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models[J], Experimental Cell Research, 2019, 380(2): 141-148.

4）Shijing Wang; Hui Wen; Wenyi Fei, Yuhong Zhao, Yuqi Feng, Lu Kuang, Min Wang*, Min Wu*. Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models[J], American Journal of Cancer Research, 2020, 10(8)：2387-2408. 

5）Yuhong Zhao , Shijing Wang, Wenyi Fei, Yuqi Feng, Le Shen, Xinyu Yang , Min Wang* and Min Wu*. Prediction of anticancer peptides with high efficacy and low toxicity by hybrid model based on 3D structure of peptides[J]. International Journal of Molecular Sciences. 2021, 22(11):5630.

1．Study on the Antitumor Activity and Mechanism of Bispecific Antibodies Targeting DLL4 and VEGF

2. Metabolic regulation of daptomycin biosynthesis genes and construction of high-yield genetically engineered bacteria